Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats

Sarah E. Maggio, Meredith A. Saunders, Thomas A. Baxter, Kimberly Nixon, Mark A. Prendergast, Guangrong Zheng, Peter Crooks, Linda P. Dwoskin, Rachel D. Slack, Amy H. Newman, Richard Bell, Michael T. Bardo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Rationale: Co-users of alcohol and nicotine are the largest group of polysubstance users worldwide. Commonalities in mechanisms of action for ethanol (EtOH) and nicotine proposes the possibility of developing a single pharmacotherapeutic to treat co-use. Objectives: Toward developing a preclinical model of co-use, female alcohol-preferring (P) rats were trained for voluntary EtOH drinking and i.v. nicotine self-administration in three phases: (1) EtOH alone (0 vs. 15%, two-bottle choice), (2) nicotine alone (0.03 mg/kg/infusion, active vs. inactive lever), and (3) concurrent access to both EtOH and nicotine. Using this model, we examined the effects of (1) varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist with high affinity for the α4β2* subtype; (2) r-bPiDI, a subtype-selective antagonist at α6β2* nAChRs; and (3) (R)-modafinil, an atypical inhibitor of the dopamine transporter (DAT). Results: In phases 1 and 2, pharmacologically relevant intake of EtOH and nicotine was achieved. In the concurrent access phase (phase 3), EtOH consumption decreased while nicotine intake increased relative to phases 1 and 2. For drug pretreatments, in the EtOH access phase (phase 1), (R)-modafinil (100 mg/kg) decreased EtOH consumption, with no effect on water consumption. In the concurrent access phase, varenicline (3 mg/kg), r-bPiDI (20 mg/kg), and (R)-modafinil (100 mg/kg) decreased nicotine self-administration but did not alter EtOH consumption, water consumption, or inactive lever pressing. Conclusions: These results indicate that therapeutics which may be useful for smoking cessation via selective inhibition of α4β2* or α6β2* nAChRs, or DAT inhibition, may not be sufficient to treat EtOH and nicotine co-use.

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalPsychopharmacology
DOIs
StateAccepted/In press - Feb 18 2018

Fingerprint

Nicotinic Agonists
Nicotinic Antagonists
Dopamine Plasma Membrane Transport Proteins
Nicotine
Ethanol
Drinking
Self Administration
Alcohols
Varenicline
modafinil
Nicotinic Receptors
Smoking Cessation

Keywords

  • (R)-modafinil
  • Alcohol
  • Co-use
  • Ethanol
  • Nicotine
  • R-bPiDI
  • Varenicline

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats. / Maggio, Sarah E.; Saunders, Meredith A.; Baxter, Thomas A.; Nixon, Kimberly; Prendergast, Mark A.; Zheng, Guangrong; Crooks, Peter; Dwoskin, Linda P.; Slack, Rachel D.; Newman, Amy H.; Bell, Richard; Bardo, Michael T.

In: Psychopharmacology, 18.02.2018, p. 1-15.

Research output: Contribution to journalArticle

Maggio, SE, Saunders, MA, Baxter, TA, Nixon, K, Prendergast, MA, Zheng, G, Crooks, P, Dwoskin, LP, Slack, RD, Newman, AH, Bell, R & Bardo, MT 2018, 'Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats', Psychopharmacology, pp. 1-15. https://doi.org/10.1007/s00213-018-4853-4
Maggio, Sarah E. ; Saunders, Meredith A. ; Baxter, Thomas A. ; Nixon, Kimberly ; Prendergast, Mark A. ; Zheng, Guangrong ; Crooks, Peter ; Dwoskin, Linda P. ; Slack, Rachel D. ; Newman, Amy H. ; Bell, Richard ; Bardo, Michael T. / Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats. In: Psychopharmacology. 2018 ; pp. 1-15.
@article{a795fc34fbbe46a58970fc480b57d34a,
title = "Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats",
abstract = "Rationale: Co-users of alcohol and nicotine are the largest group of polysubstance users worldwide. Commonalities in mechanisms of action for ethanol (EtOH) and nicotine proposes the possibility of developing a single pharmacotherapeutic to treat co-use. Objectives: Toward developing a preclinical model of co-use, female alcohol-preferring (P) rats were trained for voluntary EtOH drinking and i.v. nicotine self-administration in three phases: (1) EtOH alone (0 vs. 15{\%}, two-bottle choice), (2) nicotine alone (0.03 mg/kg/infusion, active vs. inactive lever), and (3) concurrent access to both EtOH and nicotine. Using this model, we examined the effects of (1) varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist with high affinity for the α4β2* subtype; (2) r-bPiDI, a subtype-selective antagonist at α6β2* nAChRs; and (3) (R)-modafinil, an atypical inhibitor of the dopamine transporter (DAT). Results: In phases 1 and 2, pharmacologically relevant intake of EtOH and nicotine was achieved. In the concurrent access phase (phase 3), EtOH consumption decreased while nicotine intake increased relative to phases 1 and 2. For drug pretreatments, in the EtOH access phase (phase 1), (R)-modafinil (100 mg/kg) decreased EtOH consumption, with no effect on water consumption. In the concurrent access phase, varenicline (3 mg/kg), r-bPiDI (20 mg/kg), and (R)-modafinil (100 mg/kg) decreased nicotine self-administration but did not alter EtOH consumption, water consumption, or inactive lever pressing. Conclusions: These results indicate that therapeutics which may be useful for smoking cessation via selective inhibition of α4β2* or α6β2* nAChRs, or DAT inhibition, may not be sufficient to treat EtOH and nicotine co-use.",
keywords = "(R)-modafinil, Alcohol, Co-use, Ethanol, Nicotine, R-bPiDI, Varenicline",
author = "Maggio, {Sarah E.} and Saunders, {Meredith A.} and Baxter, {Thomas A.} and Kimberly Nixon and Prendergast, {Mark A.} and Guangrong Zheng and Peter Crooks and Dwoskin, {Linda P.} and Slack, {Rachel D.} and Newman, {Amy H.} and Richard Bell and Bardo, {Michael T.}",
year = "2018",
month = "2",
day = "18",
doi = "10.1007/s00213-018-4853-4",
language = "English (US)",
pages = "1--15",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats

AU - Maggio, Sarah E.

AU - Saunders, Meredith A.

AU - Baxter, Thomas A.

AU - Nixon, Kimberly

AU - Prendergast, Mark A.

AU - Zheng, Guangrong

AU - Crooks, Peter

AU - Dwoskin, Linda P.

AU - Slack, Rachel D.

AU - Newman, Amy H.

AU - Bell, Richard

AU - Bardo, Michael T.

PY - 2018/2/18

Y1 - 2018/2/18

N2 - Rationale: Co-users of alcohol and nicotine are the largest group of polysubstance users worldwide. Commonalities in mechanisms of action for ethanol (EtOH) and nicotine proposes the possibility of developing a single pharmacotherapeutic to treat co-use. Objectives: Toward developing a preclinical model of co-use, female alcohol-preferring (P) rats were trained for voluntary EtOH drinking and i.v. nicotine self-administration in three phases: (1) EtOH alone (0 vs. 15%, two-bottle choice), (2) nicotine alone (0.03 mg/kg/infusion, active vs. inactive lever), and (3) concurrent access to both EtOH and nicotine. Using this model, we examined the effects of (1) varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist with high affinity for the α4β2* subtype; (2) r-bPiDI, a subtype-selective antagonist at α6β2* nAChRs; and (3) (R)-modafinil, an atypical inhibitor of the dopamine transporter (DAT). Results: In phases 1 and 2, pharmacologically relevant intake of EtOH and nicotine was achieved. In the concurrent access phase (phase 3), EtOH consumption decreased while nicotine intake increased relative to phases 1 and 2. For drug pretreatments, in the EtOH access phase (phase 1), (R)-modafinil (100 mg/kg) decreased EtOH consumption, with no effect on water consumption. In the concurrent access phase, varenicline (3 mg/kg), r-bPiDI (20 mg/kg), and (R)-modafinil (100 mg/kg) decreased nicotine self-administration but did not alter EtOH consumption, water consumption, or inactive lever pressing. Conclusions: These results indicate that therapeutics which may be useful for smoking cessation via selective inhibition of α4β2* or α6β2* nAChRs, or DAT inhibition, may not be sufficient to treat EtOH and nicotine co-use.

AB - Rationale: Co-users of alcohol and nicotine are the largest group of polysubstance users worldwide. Commonalities in mechanisms of action for ethanol (EtOH) and nicotine proposes the possibility of developing a single pharmacotherapeutic to treat co-use. Objectives: Toward developing a preclinical model of co-use, female alcohol-preferring (P) rats were trained for voluntary EtOH drinking and i.v. nicotine self-administration in three phases: (1) EtOH alone (0 vs. 15%, two-bottle choice), (2) nicotine alone (0.03 mg/kg/infusion, active vs. inactive lever), and (3) concurrent access to both EtOH and nicotine. Using this model, we examined the effects of (1) varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist with high affinity for the α4β2* subtype; (2) r-bPiDI, a subtype-selective antagonist at α6β2* nAChRs; and (3) (R)-modafinil, an atypical inhibitor of the dopamine transporter (DAT). Results: In phases 1 and 2, pharmacologically relevant intake of EtOH and nicotine was achieved. In the concurrent access phase (phase 3), EtOH consumption decreased while nicotine intake increased relative to phases 1 and 2. For drug pretreatments, in the EtOH access phase (phase 1), (R)-modafinil (100 mg/kg) decreased EtOH consumption, with no effect on water consumption. In the concurrent access phase, varenicline (3 mg/kg), r-bPiDI (20 mg/kg), and (R)-modafinil (100 mg/kg) decreased nicotine self-administration but did not alter EtOH consumption, water consumption, or inactive lever pressing. Conclusions: These results indicate that therapeutics which may be useful for smoking cessation via selective inhibition of α4β2* or α6β2* nAChRs, or DAT inhibition, may not be sufficient to treat EtOH and nicotine co-use.

KW - (R)-modafinil

KW - Alcohol

KW - Co-use

KW - Ethanol

KW - Nicotine

KW - R-bPiDI

KW - Varenicline

UR - http://www.scopus.com/inward/record.url?scp=85042122861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042122861&partnerID=8YFLogxK

U2 - 10.1007/s00213-018-4853-4

DO - 10.1007/s00213-018-4853-4

M3 - Article

C2 - 29455292

AN - SCOPUS:85042122861

SP - 1

EP - 15

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

ER -